Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study

Scarmeas, Nikolaos; Daskalaki, Argyro; Kalligerou, Faidra; Ntanasi, Eva; Mamalaki, Eirini; Gargalionis, Antonios N.; Patas, Kostas; Chatzipanagiotou, Stylianos; Yannakoulia, Mary; Constantinides, Vasilios C.

doi:10.3390/medicina58091179

Open AccessArticle

Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study

by

Nikolaos Scarmeas

^1,2,†,

Argyro Daskalaki

^1,*,†,

Faidra Kalligerou

¹,

Eva Ntanasi

¹,

Eirini Mamalaki

³,

Antonios N. Gargalionis

⁴,

Kostas Patas

⁴,

Stylianos Chatzipanagiotou

⁴

,

Mary Yannakoulia

³ and

Vasilios C. Constantinides

¹

1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, 11528 Athens, Greece

²

Taub Institute for Research in Alzheimer’s Disease and the Aging Brain, The Gertrude H. Sergievsky Center, Department of Neurology, Columbia University, New York, NY 10032, USA

³

Department of Nutrition and Diatetics, Harokopio University, 17671 Athens, Greece

⁴

Department of Medical Biopathology, Aiginition Hospital, 11528 Athens, Greece

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Medicina 2022, 58(9), 1179; https://doi.org/10.3390/medicina58091179

Submission received: 2 August 2022 / Revised: 23 August 2022 / Accepted: 25 August 2022 / Published: 30 August 2022

(This article belongs to the Special Issue Biomarkers in Alzheimer Disease and Other Dementias: What’s Next into Pathophysiology to Support Clinical Practice and Drug Development)

Download

Browse Figure

Review Reports Versions Notes

Abstract

Background and Objectives: This article presents data from the ongoing Aiginition Longitudinal Biomarker Investigation of Neurodegeneration study (ALBION) regarding baseline clinical characterizations and CSF biomarker profiles, as well as preliminary longitudinal data on clinical progression. Materials and Methods: As of March 2022, 138 participants who either were cognitively normal (CN, n = 99) or had a diagnosis of mild cognitive impairment (MCI, n = 39) had been recruited at the specialist cognitive disorders outpatient clinic at Aiginition Hospital. Clinical characteristics at baseline were provided. These patients were followed annually to determine progression from CN to MCI or even dementia. CSF biomarker data (amyloid β1-42, phosphorylated tau at threonine 181, and total tau) collected using automated Elecsys^® assays (Roche Diagnostics) were available for 74 patients. These patients were further sorted based on the AT(N) classification model, as determined by CSF Aβ42 (A), CSF pTau (T), and CSF tTau (N). Results: Of the 49 CN patients with CSF biomarker data, 21 (43%) were classified as exhibiting “Alzheimer’s pathologic change” (A+Τ– (Ν)−) and 6 (12%) as having “Alzheimer’s disease” (A+T–(N)+, A+T+(N)–, or A+T+(N)+). Of the 25 MCI patients, 8 (32%) displayed “Alzheimer’s pathologic change”, and 6 (24%) had “Alzheimer’s disease”. A total of 66 individuals had a mean follow-up of 2.1 years (SD = 0.9, min = 0.8, max = 3.9), and 15 of those individuals (22%) showed a clinical progression (defined as a worsening clinical classification, i.e., from CN to MCI or dementia or from MCI to dementia). Overall, participants with the “AD continuum” AT(N) biomarker profile (i.e., A+T–(N)–, A+T–(N)+, A+T+(N)–, and A+T+(N)+) were more likely to clinically progress (p = 0.04). Conclusions: A CSF “AD continuum” AT(N) biomarker profile is associated with an increased risk of future clinical decline in CN or MCI subjects.

Keywords: Alzheimer’s disease; biomarker; CSF biomarker; neurodegeneration; ALBION study

Share and Cite

MDPI and ACS Style

Scarmeas, N.; Daskalaki, A.; Kalligerou, F.; Ntanasi, E.; Mamalaki, E.; Gargalionis, A.N.; Patas, K.; Chatzipanagiotou, S.; Yannakoulia, M.; Constantinides, V.C. Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study. Medicina 2022, 58, 1179. https://doi.org/10.3390/medicina58091179

AMA Style

Scarmeas N, Daskalaki A, Kalligerou F, Ntanasi E, Mamalaki E, Gargalionis AN, Patas K, Chatzipanagiotou S, Yannakoulia M, Constantinides VC. Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study. Medicina. 2022; 58(9):1179. https://doi.org/10.3390/medicina58091179

Chicago/Turabian Style

Scarmeas, Nikolaos, Argyro Daskalaki, Faidra Kalligerou, Eva Ntanasi, Eirini Mamalaki, Antonios N. Gargalionis, Kostas Patas, Stylianos Chatzipanagiotou, Mary Yannakoulia, and Vasilios C. Constantinides. 2022. "Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study" Medicina 58, no. 9: 1179. https://doi.org/10.3390/medicina58091179

APA Style

Scarmeas, N., Daskalaki, A., Kalligerou, F., Ntanasi, E., Mamalaki, E., Gargalionis, A. N., Patas, K., Chatzipanagiotou, S., Yannakoulia, M., & Constantinides, V. C. (2022). Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study. Medicina, 58(9), 1179. https://doi.org/10.3390/medicina58091179

Article Menu

Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI